Physician profile
Jeriel Weitz
NPI 1932648524
$3,679.10
in general payments reported to CMS, 2019-2025
26 companies · $745 in 2025
The $745 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $768 · 2023: $1,211 · 2024: $642 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.10 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.16 | 2021-2025 | Botox, Rinvoq |
| Merz North America, INC. | $426.07 | 2023-2024 | |
| Janssen Biotech, INC. | $335.35 | 2022-2023 | Tremfya |
| Genzyme Corporation | $152.39 | 2022-2024 | |
| Incyte Corporation | $131.74 | 2021-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $129.37 | 2021-2025 | |
| Pfizer INC. | $127.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $96.56 | 2022-2024 | |
| Galderma Laboratories, L.P. | $93.67 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.31 | 2022-2025 | Dupixent |
| Allergan, INC. | $82.72 | 2022 | |
| Lilly USA, LLC | $77.19 | 2021-2025 | Ebglyss |
| Amgen INC. | $68.38 | 2023 | Otezla |
| Medtronic, INC. | $46.34 | 2025 | Closurefast |
| Clozex Medical INC | $39.47 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $28.21 | 2025 | Spinosad, Natroba |
| Organon LLC | $27.14 | 2025 | |
| Almirall LLC | $24.89 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.75 | 2025 | |
| Smith+Nephew, INC. | $24.16 | 2024 | Pico 14 |
| Epi Health, LLC | $20.51 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.49 | 2023 | |
| Kerecis Limited | $20.08 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Verrica Pharmaceuticals INC. | $18.55 | 2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.31 | 2025 | Jublia, Cabtreo |
| Biofrontera INC. | $17.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeriel Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.